title: Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes.
abstract: OBJECTIVE
  To describe return to normal function, productivity, and satisfaction of patients with moderate or severe migraine attacks treated with combined sumatriptan/naproxen sodium, sumatriptan alone, naproxen sodium alone, or placebo.
  
  
  METHODS
  Patients in 2 identical, US, phase 3, randomized, double-blind, parallel-group, placebo-controlled, single-dose, multicenter studies treated a single moderate or severe migraine attack with sumatriptan/naproxen sodium (85 mg sumatriptan formulated with RT Technology and 500 mg naproxen sodium in a single-tablet formulation), sumatriptan, naproxen sodium, or placebo.
  
  
  METHODS
  Ability to function (not impaired, mildly impaired, severely impaired, or required bed rest) was collected in diary cards completed immediately prior to treatment, every 30 minutes for the first 2 hours, and hourly from 2 to 24 hours while awake. Patients completed the Productivity Assessment Questionnaire (PAQ) 24 hours after study drug administration. The Patient Perception of Migraine Questionnaire (PPMQ) was administered at screening and 24 hours post treatment to capture patient satisfaction.
  
  
  RESULTS
  Compared with the other groups, the sumatriptan/naproxen sodium group reported significantly higher levels of normal or mildly impaired functioning as early as 2 and 4 hours after dosing. They also demonstrated greater reductions in workplace productivity loss compared with placebo in both studies, and were consistently more satisfied with their treatment compared with patients in other treatment groups and compared with their usual medications.
  
  
  CONCLUSIONS
  Treatment with sumatriptan/naproxen sodium allowed significantly more subjects to return to normal or mildly impaired functioning more quickly, and sumatriptan/naproxen sodium patients were significantly more satisfied with their treatment compared with other treatment groups. Overall productivity loss was significantly reduced following use of sumatriptan/naproxen sodium.
authors.affiliation: Wesley Neurology Clinic, Memphis, Tennessee, USA. wesleyhead@aol.com
authors.forename: Stephen
authors.initials: S
authors.lastname: Landy
authors.forename: Sarah E
authors.initials: SE
authors.lastname: DeRossett
authors.forename: Alan
authors.initials: A
authors.lastname: Rapoport
authors.forename: John
authors.initials: J
authors.lastname: Rothrock
authors.forename: Michael H
authors.initials: MH
authors.lastname: Ames
authors.forename: Susan A
authors.initials: SA
authors.lastname: McDonald
authors.forename: Steven P
authors.initials: SP
authors.lastname: Burch
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D004311:Double-Blind Method; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D009288:Naproxen / Q000008:administration & dosage*; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D015990:Placebo Effect; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D018170:Sumatriptan / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D009288:Naproxen; D018170:Sumatriptan